SM

Stephane Mendras

'Hands-On' Medical Devices Leader I Entrepreneur/Intrapreneur I Business Angel Investor

Geneva, Geneva

Invests in

Stages:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Member Board of Directors (SaagHA SAS)

    2023

  • Vice President International

    2022

    A San-Francisco based JV between Verily (Google Life Sciences) and Santen, harnessing the convergence of AI, microelectronics and scalable digital technologies to treat eye diseases.

  • Active Member / Business Angel

    2022

    First European investment network of Business Angeles specialized in healthcare. ACTIVE INVESTOR & SUPPORTER : - A biotech company specialized in veterinary regenerative medicine that is leveraging the unique biological potential of neonatal stem cells to promote the harmonious healing of injuries or dampen inflammatory chronic diseases. - The all in one fertility platform - making the fertility journey effortless and empowering - being powered by AI, backed by science. - A biotech company with a unique approach in active personalized cancer immunotherapy, by harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens - Device company developing a unique patient monitoring solution, able to measure all vital signs, including blood pressure, in one device. - A regenerative medicine project that aims at developing breast regeneration solutions by 3D bioprinting for women who had mastectomy following breast cancer.

  • Member of the Board of Advisors

    2019

    Seenel Imaging is dedicated to functional Neuroimaging technology. We launched in 2019 a breakthrough research device combining EEG & fNIRS further to 10 years of Academic research. Medelopt® is a wearable High Resolution NIRS/EEG device with unique features on the market.

2017 - 2022

  • Global Head, Surgical

    2021 - 2022

  • Director, Surgical Devices EMEA

    2017 - 2021

    RESPONSABILITY : - Structure and develop an independent business-unit dedicated to surgical devices. - Support the integration of InnFocus Ltd. following its US$225m+ acquisition. - Build and develop a dedicated team to launch PRESERFLO MicroShunt across Europe. ACHIEVEMENT : - Established PRESERFLO MicroShunt as the preferred surgical option for advanced glaucoma patients' management. - Built & managed a dedicated team of Surgical Partners across Europe, with all necessary support functions (Medical Affairs, Market-Access, Marketing, Commercial Excellence). - Established the Surgical Division as the fastest-growing franchise (revenue & profit) within Santen.

  • Sr. Director, Business Expansion EMEA

    2015 - 2016

    ** Covidien (ex- Tyco Healthcare), acquired by Medtronic in 2015 ** RESPONSABILITY : - Built the MITG Procedural Solutions Program & developed the franchise across EMEA. - Managed the MITG OEM Business-Unit. ACHIEVEMENT : - Established the Procedural Solution Offering for hernia, colorectal, bariatric and thoracic surgical procedures. - Commercial launch across 20+ countries (annuel revenue >US$50m).

  • Director, Business Development, Licensing and Custom Product Solutions Europe

    2011 - 2014

    RESPONSABILITY : - Develop opportunities for sales and margin growth by identifying and executing product sourcing, and channel outsourcing via strategic industry partnerships. - Manage the Covidien Custom Product Solutions division across Europe. - Represent Covidien Europe in large corporate projects (value-segments, M&A, assessment of new business segment). ACHIEVEMENT : - Extended Covidien Custom Product Solutions (CPS) presence into dental, pharma industry, medical devices, rehabilitation and surgical kit-packers market (annual revenue >US20m). - Licensed multiple new products for commercialization by Covidien Medical Supply under private-labels.

2006 - 2010

  • Head of Direct Sales

    2008 - 2010

    ** Co-Founder / Anteis developed, manufactured and commercialized injectable medical devices made of hyaluronic acid (HA) dedicated to medical aesthetic, surgical ophthalmology and orthopedics ** RESPONSABILITY : - Direct-sales management through affiliates in France and Germany - Evaluate market potential and feasibility towards additional direct market entry (Japan/Brazil) ACHIEVEMENT : - Implement and scale-up dedicated teams across affiliates (25+ people) - Established a JV in Japan, gaining 30% market-share in less than 3 years - Generate >20% of the total company revenue through direct sales

  • Director, Corporate & Business Development

    2006 - 2010

    RESPONSABILITY : - Fundraising - Strategic Partnership - B-to-B Franchise ACHIEVEMENT : - US$25m fundraised through 3 leading international VCs - Strategic collaboration with Merz Pharmaceuticals - Double-digit annual growth of the B2B franchise, through large partnerships (Sanofi-Aventis) ** ACQUIRED BY MERZ PHARMA GROUP (TODAY MERZ AESTHETICS) **

2003 - 2006

  • Sr. Manager, Operations

    2003 - 2006

    ** Co-Founder / Development & commercialization of innovative surgical procedures & products for cataract surgery ** RESPONSABILITY : - Product Development - Clinical & Regulatory Affairs - Supplier Management - Supply-Chain & Customer Service ACHIEVEMENT : - Established new surgical concept for small incision cataract surgery (against induced astigmatism) - Quality System (ISO 13485/9001) & Products Registration in 40+ countries ** ACQUIRED BY CROMA-PHARMA IN 2006 **

  • Sr. Analyst, Strategic Growth

    2002 - 2003

    ** Surgical and contact lens care businesses spun-off from Allergan (2002). Today J&J Vision ** RESPONSABILITY : - Support corporate strategic planning activities - Support M&A and Strategic Partnership initiatives